# Silicon INSITE

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/silicon-insite

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.silicontx.com
- Total disclosed funding: $15M
- Latest round: Series A (Oct 19, 2016)
- Investors on record: 1

## About

Silicon INSITE, Inc. is a Boston-based company focused on developing innovative solutions for severe autoimmune and pulmonary diseases through advanced therapeutic technologies.Founded in 2016 and headquartered in Boston, US, Silicon INSITE, Inc. specializes in creating transformative medicines. The company was acquired in February 2021 for USD 450 million by Roivant Sciences, a portfolio company of various investors, including Dexcel Pharma Technologies Ltd. and NovaQuest Capital Management. The founder, Roger Pomerantz, has a history in the pharmaceutical sector, having previously established other ventures. Since its inception, the company has conducted 2 significant deals, with the most recent acquisition marking a pivotal moment in its operational strategy.Silicon INSITE, Inc. develops innovative therapies targeting severe autoimmune diseases and pulmonary disorders. The company’s portfolio includes investigational drugs such as Immunovant, which addresses autoimmune conditions; Priovant, focusing on severe autoimmune diseases; and Pulmovant, aimed at pulmonary diseases. These products are under development for markets in North America and Europe, leveraging advanced technology throughout the drug discovery and commercialization phases.Silicon INSITE, Inc. generates revenue through strategic partnerships primarily based on licensing agreements with larger pharmaceutical firms. These collaborations often involve shared development costs and milestones linked to clinical outcomes, ensuring capital efficiency while advancing their investigational therapies. Specific revenue figures associated with individual products are not disclosed, yet the company’s main offerings are integrated within a high-investment market for serious medical conditions.Following the acquisition on February 26, 2021, Silicon INSITE, Inc. plans to enhance its product pipeline, focusing on the development and launch of new therapies for autoimmune and pulmonary diseases. Expansion efforts aim to penetrate additional international markets in Europe by 2024. The recent funding of USD 450 million will facilitate research and development initiatives and the launch of innovative products in these targeted regions.

## Funding rounds

- Series A, Oct 19, 2016, $15M — Chengwei Capital

## Investors

- Chengwei Capital (https://capitalatlas.ai/funds/chengwei-capital) — Series A